SOURCE: Edwards Lifesciences

Edwards Lifesciences

October 04, 2010 14:00 ET

Edwards Lifesciences Opens New Facility in Utah

SALT LAKE CITY, UT--(Marketwire - October 4, 2010) -  Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has opened a new facility in Draper, Utah that will enable the company to significantly expand its manufacturing and development capabilities, and accommodate its plans for growth. 

"We look forward to providing a rewarding environment in which our employees can thrive in producing technologies to address the unmet needs of clinicians and their patients suffering from cardiovascular disease and critical illnesses," said Michael A. Mussallem, chairman and CEO of Edwards Lifesciences. "To help fulfill this mission, we plan to hire up to 1,000 new employees at this new center in the coming years."

"We are proud to welcome the expansion of Edwards Lifesciences in the State of Utah," said Gary R. Herbert, Governor of Utah, who joined federal, state and local Draper City officials, along with hundreds of Edwards' employees and other guests at a ribbon-cutting ceremony at the facility today. "Edwards' commitment to its employees, clinicians and patients will prove to be a tremendous asset as it continues to flourish and invest in our great State." 

Edwards has begun manufacturing its cardiac surgery systems products and accessories for its transcatheter heart valve systems in Draper, and expects to transfer all of its existing operations and approximately 250 employees from its Midvale facility to Draper by the end of the year.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at www.edwards.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "expect," "intend," "guidance," or other similar expressions and include, but are not limited to, the Company's growth and employment projections, and its plans for transferring operations and employees from the Midvale to Draper facility. Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the Company does update or correct one or more of these statements, investors and others should not conclude that the Company will make additional updates or corrections.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include those and other risks detailed in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2009.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

Contact Information

  • Media Contact:
    Amanda C. Fowler
    949-250-5070

    Investor Contact:
    David K. Erickson
    949-250-6826